Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety and efficacy of VTE prophylaxis for 3 modality regimens
(Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg
SQ q12 hours) in adult patients (≥18 y/o) with severely burn injuries (BSA≥20%) by measuring
the bleeding incidence and VTE events.
Phase:
N/A
Details
Lead Sponsor:
King Abdullah International Medical Research Center